pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Gene Therapy (AAV) · news · pharmadog
← back to Gene Therapy (AAV)
News · Gene Therapy (AAV)
527
stories
16d
STAT+: Psilocybin’s lasting benefits prove elusive in mice
stat
16d
UniQure gets review date and adcomm; Inovio's stock surges after approval
endpoints
16d
FDA grants uniQure’s Huntington’s gene therapy priority review, teeing up ‘defining milestone’
fiercebiotech
16d
Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune push
biospace
16d
UniQure snags May Day decision date for Huntington’s gene therapy after arduous year
biospace
16d
FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality
fda press
16d
Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
biospace
17d
BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
biospace
17d
FDA finalizes cell and gene therapy potency guidance
raps
20d
Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson’s
biopharma dive
20d
Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retires
fiercebiotech
20d
STAT+: Vertex kidney disease drug scrutinized for infection risk
stat
20d
Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations
fiercebiotech
20d
Stability, speed and strategy: Inside Australia’s early‑stage edge
biospace
20d
Opinion: Health care needs buyers willing to say no
stat
21d
FDA unveils guidance for ‘plug and play’ gene therapies
biopharma dive
21d
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
biospace
21d
STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
stat
21d
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
stat
21d
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
stat
21d
STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
stat
22d
Backed by Amish and Mennonites, a new kind of gene therapy company takes shape
endpoints
22d
STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
stat
22d
STAT+: RFK Jr. goes for broke in Iowa
stat
22d
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
biopharma dive
22d
STAT+: Nonprofit resurrects shelved gene therapy after startup shuts down
stat
22d
A possible treatment for brain-eating amoebas, found in the sea
stat
22d
Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
fiercebiotech
22d
STAT+: Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own
stat
24d
Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
biospace
← prev
page 4 of 18
next →